Alnylam Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.12.24	REGN : Poze-Cemdi Combo In Phase 3 Result Shows Superior Hemolysis Control In PNH Vs. Ravulizumab (RTTNews)
17.11.24	Alnylam Presents New Phase 1 Results For Next-Gen RNAi Therapy Nucresiran In ATTR Amyloidosis (RTTNews)
31.10.24	Alnylam Pharmaceuticals Inc. Q3 Earnings Summary (RTTNews)
16.10.24	Alnylam Pharma Submits Type II Variation To European Medicines Agency For Vutrisiran (RTTNews)
09.10.24	Alnylam Submits SNDA For Vutrisiran To Treat ATTR Amyloidosis With Cardiomyopathy (RTTNews)
29.09.24	Alnylam : Phase 3 Study Data Support Potential Of Vutrisiran In ATTR Amyloidosis With Cardiomyopathy (RTTNews)
30.08.24	Alnylam Pharma Down 11% In Pre-market Despite Positive Data From HELIOS-B Phase 3 Study (RTTNews)
01.08.24	Alnylam Pharmaceuticals Inc. Q2 Earnings Summary (RTTNews)
24.06.24	Alnylam Surges In Pre-market After Its Heart Disease Drug Meets Primary Goal In Late-stage Study (RTTNews)
24.06.24	Alnylam Says Phase 3 HELIOS-B Study Of Vutrisiran Met Primary Goal (RTTNews)
02.05.24	Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates (RTTNews)
30.04.24	Alnylam, Medison Expand Partnership To Market RNAi Therapeutics In Addnl. LATAM And APAC Markets (RTTNews)
07.04.24	Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC (RTTNews)
15.02.24	Alnylam Pharmaceuticals Inc. Q4 Loss Decreases, beats estimates (RTTNews)
08.01.24	Alnylam Pharma Announces Preliminary 2023 Global Net Product Revenue (RTTNews)
13.12.23	Alnylam Pharma Announces Product And Pipeline Goals (RTTNews)
02.11.23	Alnylam Pharmaceuticals Inc. Q3 Earnings Summary (RTTNews)
25.10.23	Alnylam Pharma Reports Additional Positive Interim Phase 1 Results For Alzheimer's Disease Treatment (RTTNews)
09.10.23	Alnylam Pharma Decides Not To Pursue Expanded Indication For Patisiran In The U.S. (RTTNews)
13.09.23	Alnylam Pharmaceuticals: FDA Committee To Review SNDA For Patisiran; Trading Halted (RTTNews)
07.09.23	Alnylam: KARDIA-1 Phase 2 Dose-Ranging Study Of Zilebesiran Meets Primary Endpoint (RTTNews)
31.08.23	Biotech Stocks Facing FDA Decision In September 2023 (RTTNews)
26.08.23	Alnylam Pharma To Appeal U.S. Court Ruling On Two Patents Asserted Against Moderna (RTTNews)
03.08.23	Alnylam Pharmaceuticals Inc. Q2 Loss Decreases, but misses estimates (RTTNews)
24.07.23	Alnylam, Roche Partner To Co-Develop, Co-Commercialize Zilebesiran (RTTNews)
17.07.23	Alnylam Presents ALN-APP's Updated Positive Interim Phase 1 Results In Alzheimer's Disease, CAA (RTTNews)
30.06.23	Alnylam's Onpattro To Be Reviewed By FDA Panel In September (RTTNews)
04.05.23	Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates (RTTNews)
09.03.23	Alnylam Pharma To Extend Its Existing Relationship With Medison (RTTNews)
09.03.23	Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics (PR Newswire)
23.02.23	Alnylam Pharmaceuticals Inc. Q4 Loss Decreases, beats estimates (RTTNews)
21.02.23	Alnylam Pharma : FDA Accepts SNDA For Patisiran For Treatment Of Cardiomyopathy Of ATTR Amyloidosis (RTTNews)
09.01.23	Alnylam Announces Preliminary Q4 Global Net Product Revenues (RTTNews)
21.12.22	Alnylam Pharma Submits CTA Application For ALN-KHK For Treatment Of Type 2 Diabetes (RTTNews)
28.10.22	ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook (RTTNews)
27.10.22	Alnylam Pharmaceuticals Inc. Q3 Loss Increases, but beats estimates (RTTNews)
07.10.22	Alnylam's Oxlumo Indicated For Treatment Of PH1 To Lower Urinary And Plasma Oxalate Levels (RTTNews)
30.09.22	Biotech Stocks Facing FDA Decision In October 2022 (RTTNews)
20.09.22	Alnylam's AMVUTTRA Gets Approval In Europe To Treat Hereditary Transthyretin-mediated Amyloidosis (RTTNews)
15.09.22	Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers (PR Newswire)
08.09.22	Alnylam Presents Positive Results From Phase 3 Study Of Patisiran In ATTR Amyloidosis (RTTNews)
29.08.22	Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of proteinuria (RTTNews)
03.08.22	Alnylam : Phase 3 Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy Meets Main Goal (RTTNews)
29.07.22	Alnylam Q2 Loss Widens, SGEN Boosts Revenue Outlook, NVCR To Report LUNAR Study Data In Q1 (RTTNews)
28.07.22	Alnylam Pharmaceuticals Net Loss Widens In Q2 (RTTNews)
28.07.22	Alnylam Pharmaceuticals Inc. Q2 Loss Decreases, but misses estimates (RTTNews)
09.06.22	Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran (RTTNews)
18.05.22	Alnylam Pharma Says Canada Authorizes OXLUMO For Treatment Of Primary Hyperoxaluria Type 1 (RTTNews)
29.04.22	ACCD Guides Q1 Well Below Analysts' Estimates, ALNY Cuts Outlook, NVCR Braces For Busy Year (RTTNews)
28.04.22	Alnylam Pharmaceuticals Inc. Q1 Loss Decreases, beats estimates (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alnylam Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten